Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Trading Statement

6 Jun 2013 07:00

RNS Number : 4128G
BATM Advanced Communications Ld
06 June 2013
 



6 June 2013

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update

 

BATM Advanced Communications Limited (LSE: BVC; TASE: BATM), a leading provider of real-time technologies for the networked telecoms and medical laboratory equipment markets, provides the following update on trading.

 

As stated in the Group's interim management statement for the first quarter of 2013, BATM was on schedule to deliver solid growth in 2013. At the beginning of Q2 2013, the Group was gearing up its production in the Medical division businesses of diagnostics and pathogenic waste management in response to significant demand for its products. In order to meet this demand in the diagnostics business, BATM also increased spending on seeking registration. Disappointingly, components supplied by third parties failed to arrive during May as scheduled, and consequently BATM was unable to fulfill orders and was forced to postpone deliveries. However, the backlog remains substantial and, with certain components required to complete some orders having been received, the Group is working towards clearing this in the second half of 2013.

 

Separately, due to ongoing global economic and commercial uncertainty, the Group has re-enforced its policy of tight credit control for certain customers of the distribution business of the Medical division whereby shipping should only occur once payment has been received by BATM or it has complete confidence that payment will be forthcoming. Consequently, and in accordance with this policy, the Group was forced to stop supplies to certain major customers globally during May 2013. This has resulted in revenues in this business being lower than anticipated.

 

The consequence of the above factors is that the Group expects first half 2013 revenue and profit to be materially below management's expectations. In contrast, the Group has opened trading in June 2013 very well and its businesses are returning to normality. Accordingly, the Group expects H2 2013 performance to be in line with management's expectations. For the full year to 31 December 2013 as a whole, the Group still expects to achieve higher revenue and profit than for the full year to 31 December 2012.

 

Looking ahead, the fundamentals of the business remain strong. BATM's Telecom division's T-Metro 8000 platform and Edge Genie service management solution continue to attract interest from customers globally. The Group has also been asked to join consortia bidding for large, long-term contracts, and the Board is confident of being awarded contracts in thenear future. In the Medical division, the diagnostics business continues to grow and has a strong order book and backlog. In addition, the Group continues to increase the installations of its Integrated Sterilizer and Shredder systems in the sterilization business.

 

CELARE, the Group's subsidiary focusing on networks security, continues to perform well in its contract with the Israeli Defence Force. Due to the growing demand for products and services to protect networks against cyber-attacks, BATM has been in discussions with the relevant authorities to allow it to market part of its product line globally. BATM anticipates successful conclusion to these talks in 2013 and has accelerated its strategic plan for this business.

 

BATM will provide further details on trading for the first half of the year in its interim results announcement in August 2013.

Enquiries 

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Ofer Bar-Ner, Chief Financial Officer

finnCap

Stuart Andrews, Henrik Persson - Corporate Finance

+44 20 7220 0500

Brian Patient, Stephen Norcross - Corporate Broking

Shore Capital

Pascal Keane

+44 20 7408 4090 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVELFBXQFFBBD
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.